Unlocking the Secrets of Immune Checkpoints: Pioneering New Frontiers in Cancer Therapy

Unlocking the Secrets of Immune Checkpoints: Pioneering New Frontiers in Cancer Therapy

At the forefront of cancer treatment, immune checkpoints are emerging as game-changing factors. These remarkable molecules act as the immune system’s “brakes,” normally helping to regulate immune responses and prevent excessive damage. However, tumor cells often exploit these “brakes” to evade immune surveillance. Fortunately, scientists have discovered ways to “release” these brakes, enabling the immune system to resume its potent anti-tumor activity.

Uprotein is committed to providing you with high-quality immune checkpoint-related proteins to support your scientific exploration. Our rigorously validated products cover a wide range of popular immune checkpoint proteins, including PD-1, CTLA-4, LAG-3, TIM-3, TIGIT, PD-L1, and others. These proteins play pivotal roles in tumor immunotherapy and serve as essential tools for researching and developing novel immunotherapeutic approaches.

Immune Checkpoint Proteins

• PD-1 (Programmed Cell Death Protein 1): A checkpoint molecule expressed on T cells, PD-1 inhibits T cell activity by binding to its ligand PD-L1, allowing tumor cells to evade immune attack. PD-1 inhibitors such as Nivolumab and Pembrolizumab are now widely used in treating various cancers.

• 

• CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4): An inhibitory receptor on T cells, CTLA-4 suppresses T cell activation by binding to B7 family ligands. The CTLA-4 inhibitor Ipilimumab has demonstrated remarkable efficacy in cancers such as melanoma.

• 

• LAG-3 (Lymphocyte-Activation Gene 3): An immunosuppressive molecule that inhibits T cell activity by binding to MHC-II. The LAG-3 inhibitor Relatlimab, used in combination with PD-1 inhibitors, has shown promise in advanced melanoma treatment.

• 

• TIM-3 (T-Cell Immunoglobulin and Mucin-Domain Containing-3): By binding to Galectin-9, TIM-3 induces T cell apoptosis and promotes immunosuppression. TIM-3 inhibitors are emerging as key candidates for tumor immunotherapy.

• 

• TIGIT (T-Cell Immunoreceptor with Ig and ITIM Domains): TIGIT inhibits T cell and NK cell activity by binding to CD155, facilitating tumor immune evasion. The TIGIT inhibitor Tiragolumab is exhibiting promising anti-tumor activity in clinical trials.

• 

Choose Uprotein, Embark on a New Journey in Immunotherapy

Immune checkpoint proteins represent a new beacon of hope in cancer therapy, and Uprotein is your reliable research partner. Our high-quality protein products, backed by extensive validation data, provide robust support for your studies. Whether for fundamental research or clinical application development, Uprotein is equipped to meet your needs.

Join us in exploring the mysteries of immune checkpoints and driving breakthroughs in cancer treatment!

Currently Available Products: